P16.02 Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience

Abstract

The IMpower 150 study demonstrated that the addition of atezolizumab and bevacizumab to platinum-doublet chemotherapy resulted in significant improvement in survival, albeit with high rates of treatment-related adverse events. There are limited real world data on the efficacy and toxicity of this regimen to guide routine clinical practice particularly in pre-treated patients (pts) and in those with oncogene driven and leptomeningeal disease.